Abstract | BACKGROUND: METHODS: Fifty-four patients with non- hormone-sensitive cancer, generally characterized by substantial weight loss and hypermetabolism, received either MPA, 500 mg, or placebo twice daily for 12 weeks (double-blind study). Food intake was measured by dietary history, body composition was assessed by deuterium dilution (fat mass, fat-free mass), and REE was obtained by indirect calorimetry. RESULTS: Compared with placebo, 12 weeks of MPA led to an increase in energy intake (between-group difference, 426 kcal/day; P = 0.01) that was significantly associated (r = 0.68, P = 0.003) with an increase in fat mass (between-group difference, 2.5 kg; P = 0.009). Fat-free mass was not significantly influenced. REE increased during MPA treatment: at 6 weeks, the between-group difference in change was 135 kcal/day (P = 0.009); after 12 weeks, this difference was 93 kcal/ day (P = 0.07). CONCLUSIONS: The authors conclude that MPA is able to stimulate increased food intake significantly and to reverse fat loss concomitantly in patients with non- hormone-sensitive cancer.
|
Authors | J P Simons, A M Schols, J M Hoefnagels, K R Westerterp, G P ten Velde, E F Wouters |
Journal | Cancer
(Cancer)
Vol. 82
Issue 3
Pg. 553-60
(Feb 01 1998)
ISSN: 0008-543X [Print] United States |
PMID | 9452274
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Progesterone Congeners
- Medroxyprogesterone Acetate
|
Topics |
- Aged
- Appetite
(drug effects)
- Body Composition
(drug effects)
- Cachexia
(etiology, therapy)
- Double-Blind Method
- Eating
(drug effects)
- Energy Metabolism
(drug effects)
- Female
- Humans
- Male
- Medroxyprogesterone Acetate
(therapeutic use)
- Neoplasms
(complications)
- Progesterone Congeners
(therapeutic use)
- Weight Loss
|